Immunic, Inc. Engages in Medical Conferences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy IMUX?
Source: PRnewswire
- Clinical Trial Progress: Immunic's ongoing phase 3 clinical trial for IMU-838 is expected to release top-line data by the end of 2026, which could provide new treatment options for relapsing multiple sclerosis and significantly enhance the company's market position in the biopharmaceutical sector.
- Innovative Drug Mechanism: IMU-838 acts as a first-in-class Nurr1 activator, combining neuroprotective, anti-inflammatory, and antiviral effects by selectively inhibiting dihydroorotate dehydrogenase (DHODH), a unique mechanism that may confer competitive advantages to the company.
- Diverse R&D Pipeline: In addition to IMU-838, Immunic is developing earlier-stage programs like IMU-856 and IMU-381, aiming to build a broader therapeutic platform addressing neurodegenerative, chronic inflammatory, and autoimmune diseases, showcasing the company's strategic focus on innovative drug development.
- Cautionary Statement: The company emphasizes the risks associated with forward-looking statements in the press release, including macroeconomic trends and uncertainties in clinical trials, reminding investors to consider various factors that could impact future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMUX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMUX
Wall Street analysts forecast IMUX stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.190
Low
3.00
Averages
4.25
High
8.00
Current: 1.190
Low
3.00
Averages
4.25
High
8.00
About IMUX
Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Immunic, Inc. Engages in Medical Conferences
- Clinical Trial Progress: Immunic's ongoing phase 3 clinical trial for IMU-838 is expected to release top-line data by the end of 2026, which could provide new treatment options for relapsing multiple sclerosis and significantly enhance the company's market position in the biopharmaceutical sector.
- Innovative Drug Mechanism: IMU-838 acts as a first-in-class Nurr1 activator, combining neuroprotective, anti-inflammatory, and antiviral effects by selectively inhibiting dihydroorotate dehydrogenase (DHODH), a unique mechanism that may confer competitive advantages to the company.
- Diverse R&D Pipeline: In addition to IMU-838, Immunic is developing earlier-stage programs like IMU-856 and IMU-381, aiming to build a broader therapeutic platform addressing neurodegenerative, chronic inflammatory, and autoimmune diseases, showcasing the company's strategic focus on innovative drug development.
- Cautionary Statement: The company emphasizes the risks associated with forward-looking statements in the press release, including macroeconomic trends and uncertainties in clinical trials, reminding investors to consider various factors that could impact future performance.
See More
Immunic, Inc. Participates in Key Medical Conferences
- Conference Participation: Immunic, Inc. will participate in the 8th Annual Neuroimmunology Drug Development Summit from April 14-16, where Chief Scientific Officer Hella Kohlhof, Ph.D., will present the lead asset vidofludimus calcium (IMU-838), showcasing its potential in treating multiple sclerosis.
- Product Presentation: At the Boston conference, Dr. Kohlhof's presentation will highlight the unique neuroprotective and anti-inflammatory properties of vidofludimus calcium, which is expected to attract industry attention and enhance the company's visibility.
- Industry Meeting Engagement: Immunic will also exhibit at the American Academy of Neurology Annual Meeting from April 18-22, with management and medical teams available at booth #3830 to engage with attendees and further promote their R&D projects.
- Clinical Trial Progress: Vidofludimus calcium is currently in phase 3 clinical trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026; positive results could significantly boost the company's stock price and market confidence.
See More
Immunic Regains Nasdaq Compliance with Minimum Bid Price
- Compliance Notification: Immunic received written notice from Nasdaq confirming that its common stock's closing bid price was at or above $1.00 per share for at least 20 consecutive business days, thereby satisfying Nasdaq's minimum bid price requirement and marking a significant compliance milestone for the company.
- Stock Price Surge: Following the compliance notification, Immunic's stock price rose 5.4% in premarket trading to $1.17 per share, indicating a positive market reaction to the restoration of compliance status, which may enhance investor confidence.
- Funding Context: Immunic recently completed a $400 million private placement, providing essential funding for future R&D and operations, further solidifying its market position and laying the groundwork for subsequent growth.
- Analyst Rating: Guggenheim recently assigned a
See More
Immunic Regains Nasdaq Compliance, Shares Rise
- Compliance Regained: Immunic, Inc. announced on March 26 that it has regained compliance with Nasdaq listing rules after its stock closed at or above $1 for 20 consecutive trading days, alleviating concerns about potential delisting and boosting investor confidence.
- Stock Price Surge: Following the compliance announcement, Immunic's shares rose approximately 6% in pre-market trading on Wednesday, indicating market optimism regarding the company's future prospects and potentially attracting more investor interest.
- Board Appointment: The company appointed Jon Congleton, CEO of Mineralys Therapeutics, to its board on Tuesday, aiming to bring in new leadership perspectives to drive strategic development and enhance governance.
- Market Dynamics: With compliance issues resolved, Immunic is positioned for stable growth on the Nasdaq Capital Market, further expanding its market share and enhancing brand influence.
See More
Immunic Regains Nasdaq Compliance with Minimum Bid Price
- Compliance Notification: Immunic received written notice from Nasdaq on March 27, 2026, confirming its compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), indicating stability in its capital market presence.
- Stock Price Performance: The notice states that Immunic's common stock closed at $1.00 or greater for at least 20 consecutive business days prior to March 26, 2026, successfully meeting Nasdaq's requirements and closing the related matter.
- Clinical Trial Progress: The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, which could positively impact future revenues.
- Pipeline Expansion: In addition to IMU-838, Immunic is developing earlier-stage programs IMU-856 and IMU-381, aimed at building a broader therapeutic platform to address neurodegenerative, chronic inflammatory, and autoimmune-related diseases, enhancing its competitive position in the market.
See More
Immunic Regains Nasdaq Compliance with Minimum Bid Price
- Compliance Notification: Immunic received a notice from Nasdaq on March 27, 2026, confirming its compliance with the minimum bid price requirement, as its common stock closed at $1.00 or above for 20 consecutive business days, indicating stability in its capital market presence.
- Clinical Trial Progress: The company's lead program, vidofludimus calcium (IMU-838), is currently in phase 3 trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, which could significantly impact its future market performance.
- Innovative Drug Mechanism: As a first-in-class Nurr1 activator, the drug combines neuroprotective effects with anti-inflammatory and antiviral properties by selectively inhibiting dihydroorotate dehydrogenase (DHODH), showcasing its potential in treating various neurological diseases.
- Diverse R&D Pipeline: In addition to IMU-838, Immunic is developing earlier-stage programs like IMU-856 and IMU-381, aimed at building a broader therapeutics platform to address neurodegenerative, chronic inflammatory, and autoimmune diseases, thereby enhancing the company's competitive edge in the market.
See More
Immunic, Inc. Engages in Medical Conferences
- Clinical Trial Progress: Immunic's ongoing phase 3 clinical trial for IMU-838 is expected to release top-line data by the end of 2026, which could provide new treatment options for relapsing multiple sclerosis and significantly enhance the company's market position in the biopharmaceutical sector.
- Innovative Drug Mechanism: IMU-838 acts as a first-in-class Nurr1 activator, combining neuroprotective, anti-inflammatory, and antiviral effects by selectively inhibiting dihydroorotate dehydrogenase (DHODH), a unique mechanism that may confer competitive advantages to the company.
- Diverse R&D Pipeline: In addition to IMU-838, Immunic is developing earlier-stage programs like IMU-856 and IMU-381, aiming to build a broader therapeutic platform addressing neurodegenerative, chronic inflammatory, and autoimmune diseases, showcasing the company's strategic focus on innovative drug development.
- Cautionary Statement: The company emphasizes the risks associated with forward-looking statements in the press release, including macroeconomic trends and uncertainties in clinical trials, reminding investors to consider various factors that could impact future performance.
See More
Immunic, Inc. Participates in Key Medical Conferences
- Conference Participation: Immunic, Inc. will participate in the 8th Annual Neuroimmunology Drug Development Summit from April 14-16, where Chief Scientific Officer Hella Kohlhof, Ph.D., will present the lead asset vidofludimus calcium (IMU-838), showcasing its potential in treating multiple sclerosis.
- Product Presentation: At the Boston conference, Dr. Kohlhof's presentation will highlight the unique neuroprotective and anti-inflammatory properties of vidofludimus calcium, which is expected to attract industry attention and enhance the company's visibility.
- Industry Meeting Engagement: Immunic will also exhibit at the American Academy of Neurology Annual Meeting from April 18-22, with management and medical teams available at booth #3830 to engage with attendees and further promote their R&D projects.
- Clinical Trial Progress: Vidofludimus calcium is currently in phase 3 clinical trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026; positive results could significantly boost the company's stock price and market confidence.
See More
Immunic Regains Nasdaq Compliance with Minimum Bid Price
- Compliance Notification: Immunic received written notice from Nasdaq confirming that its common stock's closing bid price was at or above $1.00 per share for at least 20 consecutive business days, thereby satisfying Nasdaq's minimum bid price requirement and marking a significant compliance milestone for the company.
- Stock Price Surge: Following the compliance notification, Immunic's stock price rose 5.4% in premarket trading to $1.17 per share, indicating a positive market reaction to the restoration of compliance status, which may enhance investor confidence.
- Funding Context: Immunic recently completed a $400 million private placement, providing essential funding for future R&D and operations, further solidifying its market position and laying the groundwork for subsequent growth.
- Analyst Rating: Guggenheim recently assigned a
See More
Immunic Regains Nasdaq Compliance, Shares Rise
- Compliance Regained: Immunic, Inc. announced on March 26 that it has regained compliance with Nasdaq listing rules after its stock closed at or above $1 for 20 consecutive trading days, alleviating concerns about potential delisting and boosting investor confidence.
- Stock Price Surge: Following the compliance announcement, Immunic's shares rose approximately 6% in pre-market trading on Wednesday, indicating market optimism regarding the company's future prospects and potentially attracting more investor interest.
- Board Appointment: The company appointed Jon Congleton, CEO of Mineralys Therapeutics, to its board on Tuesday, aiming to bring in new leadership perspectives to drive strategic development and enhance governance.
- Market Dynamics: With compliance issues resolved, Immunic is positioned for stable growth on the Nasdaq Capital Market, further expanding its market share and enhancing brand influence.
See More
Immunic Regains Nasdaq Compliance with Minimum Bid Price
- Compliance Notification: Immunic received written notice from Nasdaq on March 27, 2026, confirming its compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), indicating stability in its capital market presence.
- Stock Price Performance: The notice states that Immunic's common stock closed at $1.00 or greater for at least 20 consecutive business days prior to March 26, 2026, successfully meeting Nasdaq's requirements and closing the related matter.
- Clinical Trial Progress: The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, which could positively impact future revenues.
- Pipeline Expansion: In addition to IMU-838, Immunic is developing earlier-stage programs IMU-856 and IMU-381, aimed at building a broader therapeutic platform to address neurodegenerative, chronic inflammatory, and autoimmune-related diseases, enhancing its competitive position in the market.
See More
Immunic Regains Nasdaq Compliance with Minimum Bid Price
- Compliance Notification: Immunic received a notice from Nasdaq on March 27, 2026, confirming its compliance with the minimum bid price requirement, as its common stock closed at $1.00 or above for 20 consecutive business days, indicating stability in its capital market presence.
- Clinical Trial Progress: The company's lead program, vidofludimus calcium (IMU-838), is currently in phase 3 trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026, which could significantly impact its future market performance.
- Innovative Drug Mechanism: As a first-in-class Nurr1 activator, the drug combines neuroprotective effects with anti-inflammatory and antiviral properties by selectively inhibiting dihydroorotate dehydrogenase (DHODH), showcasing its potential in treating various neurological diseases.
- Diverse R&D Pipeline: In addition to IMU-838, Immunic is developing earlier-stage programs like IMU-856 and IMU-381, aimed at building a broader therapeutics platform to address neurodegenerative, chronic inflammatory, and autoimmune diseases, thereby enhancing the company's competitive edge in the market.
See More
